supplemented with 1% Tween 80 (both from Sigma-Aldrich). These drugs or their 25 solvents were administered orally (p.o.) in a volume of 10 mL/kg. 26 In addition, we also tested the effects of ruthenium red (1-2 mg/kg) (Sigma-Aldrich), 27 a nonselective TRP antagonist (St Pierre et al., 2009) . Ruthenium red was dissolved 28 in saline and administered subcutaneously (s.c.) into the interscapular zone in a 29 volume of 5 mL/kg. The control group received an equal volume of saline. 30 In all cases, behavioral evaluations after drug administration were recorded by an 31 observer blinded to the treatment. intraperitoneal injection, which has been previously reported to ablate all peripheral 4 TRPV1+ neurons (Hsieh et al., 2012) . The control group received an equal volume of 5 vehicle. All procedures were done under isoflurane anesthesia to minimize distress, 6 5 days before behavioral testing or sample collection. Ugo-Basile, Varese, Italy). The apparatus consisted of a T-shaped metal bar 11 connected to a force transducer. To measure grip strength in the hindpaws of the 12 mice, the experimenter held the mouse gently by the base of the tail, allowing the 13 animal to grasp the metal bar with its hindpaws. To prevent mice from gripping the 14 metal bar with their forepaws during the recording, the animals were first allowed to 15 grasp a wire mesh cylinder with their forepaws. As soon as the mice grasped the 16 transducer metal bar with their hindpaws, the experimenter pulled the animals 17 backwards by the tail until grip was lost (see Supplemental Video, which 18 demonstrates the procedure used to measure hindlimb grip strength). The peak 19 force of each measurement was automatically recorded in grams (g) by the device. 20 Hindlimb grip strength in each mouse was measured in triplicate. Basal grip strength 21 values were recorded for each animal as the average of two determinations on 22 different days before the administration of CFA or saline. This value was considered 23 as 100% of grip strength and used as a reference for subsequent determinations. 24 25 2.6. Measurement of von Frey threshold 26 Mechanical allodynia to a punctate stimulus was determined with a slight 27 modification of a previously described method (Chaplan et al., 1994) . Briefly, animals 28 were acclimated for 2 h in methacrylate test compartments (7.5 cm wide × 7.5 cm 29 long × 15 cm high) placed on an elevated mesh-bottomed platform, to provide 30 access to the plantar surface of the hindpaws. Plantar stimulation is the standard site monofilaments (Stoelting, Wood Dale, IL, USA), with bending forces that ranged 1 from 0.02 to 1.4 g, were applied using the up-down paradigm, starting with the 0.6 g 2 filament. Filaments were applied two times for 2-3 s, with inter-application intervals 3 of at least 30 s to avoid sensitization to the mechanical stimuli. The response to the 4 filament was considered positive if immediate licking/biting, flinching or rapid 5 withdrawal of the stimulated paw was observed. As for grip strength determinations, 6 basal values were recorded for each animal as the average of two determinations on 7 different days, before the administration of CFA or saline. This value was considered 8 100% of the von Frey threshold and used as a reference for subsequent 9 determinations. 
M A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT 6 stained with hematoxylin and eosin. Images were acquired with a Nikon Eclipse 50i 1 microscope equipped with a DS-Ri1 camera. the first 3 days after the induction of inflammation. In both dose groups, grip strength 1 values returned to normal levels, although the recovery period was longer in animals 2 given the higher volume of CFA ( Fig. 1A) . Untreated (naïve) animals and mice 3 treated periarticularly with saline (30 µL/ankle) did not show significant changes in 4 grip strength at any time-point tested for up to 21 days (Fig. 1A) .
5
CFA induced persistent ankle swelling that lasted for at least 21 days, which 6 was also dependent on the volume administered. Animals treated with 30 µL/ankle of 7 CFA had thicker ankles than those given 20 µL, whereas those treated with saline 8 (30 µL/ankle) showed no significant increase in ankle thickness ( Fig. 1B ). We used 9 30 µL CFA (or saline)/ankle in the rest of the experiments. Macroscopically, saline-10 treated animals showed no signs of paw inflammation (Fig. 1C , left panel). However,
11
CFA-treated mice had prominent inflammation that appeared to be restricted to the 12 administration site (ankle joint) and nearby areas, whereas the paw pad did not 13 appear to be affected ( Fig. 1C right panel) . Histological examination of the tibiotarsal 14 joint, synovial membrane or paw pad from mice 2 days after the administration of 15 saline did not disclose any histological anomalies ( Fig. 1D upper panels); however, 2 16 days after CFA administration we found massive periarticular immune infiltrate which 17 extended to the heel, as well as an inflammatory process in the synovial membrane 18 characterized by prominent immune infiltrate accompanied by intraarticular exudate, 19 but no histological alterations in the paw pad ( Fig. 1D , middle panels). Twenty-one 20 days after CFA administration, the animals still showed marked immune infiltration in 21 the heel and periarticular structures, but the synovial membrane showed no immune 22 infiltrate, and we did not observe appreciable intraarticular exudate, and the paw pad 23 remained unaffected ( Fig. 1D , lower panels). 24 We then measured the mechanical threshold in an inflamed (heel) and in a 25 noninflamed area (pad) of the paw. Mice given CFA showed a marked decrease in 26 the von Frey threshold in the heel, denoting the presence of tactile allodynia, and the 27 decrease was maintained throughout the time-course of study (21 days) ( Fig. 2A ).
28
Joint inflammation did not induce alterations in the mechanical threshold in the paw 29 pad ( Fig. 2A) , indicating that the sensory alterations appeared to be restricted to the 30 inflamed area. Control mice treated periarticularly with saline showed no alterations 31 in their mechanical thresholds in either the heel or the paw pad ( Fig. 2A ).
32
We also determined whether joint inflammation under our experimental 33 conditions induced other alterations such as changes in body weight or locomotion.
Animals with induced inflammation showed no changes in body weight in 1 comparison to saline-treated mice (Fig. 2B ). In addition, CFA administration did not 2 induce alterations in either vertical or horizontal locomotor activity in comparison to 3 control mice ( Fig. 2C ). Therefore, this indicates that although CFA administration 4 induced an apparent decrease in grip strength and mechanical threshold, it did not 5 significantly affect the animals' general state or general mobility. To test whether grip strength deficits were related to pain, we evaluated the effects of 10 conventional analgesics. Oral administration of the NSAIDs ibuprofen and celecoxib, 11 as well as acetaminophen, produced a dose-dependent increase in grip strength in 12 animals with joint inflammation (Fig. 3A , B and C, respectively). The maximum effect 13 of all three drugs peaked at 90 min after administration, but even at this time-point 14 grip strength in mice with induced inflammation failed to fully recover basal values. 15 Subsequently, the increase in grip strength in animals with joint inflammation induced 16 by the NSAIDs or acetaminophen gradually reverted (Fig. 3A, B and C). We also 17 tested the effects of oral administration of the opioids tramadol and oxycodone (Fig. 18 4A and B, respectively). These drugs induced a rapid recovery of physical function 19 peaking at 45 min after administration, which decreased gradually with time. In 20 contrast to the effects of NSAIDs or acetaminophen, both tramadol and oxycodone 21 induced full recovery from grip strength deficits in mice with joint inflammation (Fig. 22 4A and B, respectively). None of these analgesics was able to modify grip strength 23 values in animals without inflammation, even when administered at doses that had 24 maximal effects in mice with induced inflammation (Fig. 3A, B and C and Fig. 4A and 25 B). These results suggest that the analgesics tested improved grip strength deficits 26 by pain-specific effects rather than by altering normal motor function. 27 We then constructed the dose-response curves of drug effects at their time of Fig. 1B) , which 9 coincided with its peak effect on grip strength deficits (Fig. 4B ). This effect rapidly 10 disappeared, which is in contrast to the longer duration of its effects on grip strength doubled the doses of these drugs all of them were then able to ameliorate tactile 16 allodynia (Fig. 5B) . Therefore, although all analgesics tested were able to improve To determine the impact of motor impairment on grip strength and tactile allodynia, (to an extent similar to oxycodone), and did not ameliorate grip strength deficits, but 27 induced a parallel decrease in this functional measure (Fig. 6 ). In addition, the active 28 doses of baclofen also decreased grip strength in noninjured animals (data not 29 shown). However, ruthenium red (administered 30 min before the behavioral evaluation) was 6 able to abolish, in a dose-dependent manner, mechanical allodynia in mice with 7 inflammation but without affecting the mechanical threshold in noninjured mice (Fig.   8 7B). We were unable to test a higher dose of ruthenium red (4 mg/kg) because it 9 induced prominent side effects. The differential effects of ruthenium red on grip 10 strength deficits and tactile allodynia suggest that their mechanisms differ. Fig. 8A   19 and B, respectively). After RTX treatment we were unable to detect TRPV1 staining 20 in either the DRG (Fig. 8A) or the spinal cord dorsal horn (Fig. 8B) , reflecting the 21 ablation of TRPV1-expressing neurons including their central terminals. The ablation 22 of this nociceptive population did not affect either grip strength or mechanical 23 threshold in noninjured mice ( Fig. 8C and D, respectively). However, it was able to 24 prevent the development of mechanical allodynia in mice with inflammation ( Fig. 8D) , 25 although it had no effect on their grip strength deficits (Fig. 8C) . Therefore, grip 26 strength deficits and the decrease in the von Frey threshold during joint inflammation 27 involve the participation of different populations of primary afferents. analgesics. In addition, we show that although tactile allodynia was abolished by 2 ruthenium red or by the ablation of TRPV1-expressing neurons, deficits in grip 3 strength in mice with joint inflammation were not.
4
The time-courses of recovery from grip strength deficits and mechanical 5 allodynia differed, as the latter persisted longer than the functional deficit. The To test whether the decrease in grip strength was related to pain, we 8 investigated the effects of orally administered analgesics used for clinical treatment 9 in humans. The NSAIDs ibuprofen and celecoxib, as well as acetaminophen, Fraser et al., 1999; Overend et al., 1999) . Sensitivity to analgesic 20 treatment differed between grip strength recovery and mechanical allodynia: the 21 former was a more sensitive indicator of the effects of analgesic drugs than the latter.
22
To the best of our knowledge, the different sensitivities of tactile hypersensitivity and et al., 2012; Huntjens et al., 2009; Matson et al., 2007) . Therefore, the greater 30 sensitivity to drug-induced analgesia may be an inherent quality of these types of We conclude that monitoring grip strength deficits during joint inflammation is a 5 reliable measure of inflammatory joint pain in rodents, as it is known to be in 
